Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318747 · ClinicalTrials.gov registry record · Phase 2
Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00318747 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 140 participants.
The verdict
NCT00318747, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will test the effectiveness of an investigational treatment for patients with ragweed-induced asthma, sometimes called fall seasonal asthma. The treatment being tested is a series of anti-ragweed shots. The purpose of the study is to determine whether a short series of injections with Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC) can cause a long-lasting reduction in the symptoms of asthma that are caused by fall hay fever allergies.
Interventions
- DRUG Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318747
The ClinicalTrials.gov registry entry for NCT00318747 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC) is the first listed.
NCT00318747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318747 about?
NCT00318747 is a clinical study titled "Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug". This study will test the effectiveness of an investigational treatment for patients with ragweed-induced asthma, sometimes called fall seasonal asthma. The treatment being tested is a series of anti-ragweed shots. The purpose of the study is to determine whether a short series of injections with Amb...
What is the current status of trial NCT00318747?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2006-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00318747?
The interventions under investigation include: Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC) (DRUG).
Who is sponsoring clinical trial NCT00318747?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.